tiprankstipranks
Trending News
More News >

Immunovant price target lowered to $35 from $51 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Immunovant (IMVT) to $35 from $51 and keeps a Buy rating on the shares. The target cut reflects the company’s data readouts in 2027, with an expected potential launch in 2028.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue